Astrana Health, Inc. quarterly report, Q2 FY2014

Business context and reporting period

The supplied filing is Apollo Medical Holdings, Inc.’s Form 10-Q for the quarter and six months ended July 31, 2013—not a filing under the name Astrana Health, Inc. The company described an integrated California physician network serving Medicare, commercial and Medi-Cal beneficiaries, with more than 300 physicians as of July 31, 2013. Its activities included hospital-based physician services, practice management and an Accountable Care Organization (ACO).

Financial results and liquidity

At July 31, 2013, cash was $1.252 million, current assets were $2.752 million and current liabilities were $2.243 million. Total liabilities were $4.406 million, and stockholders’ deficit was $1.269 million. Notes payable of $594,765 included a $500,000 senior secured note due October 15, 2013 and $94,765 drawn on a $100,000 line of credit due June 5, 2014. Convertible notes had a carrying value of $2.163 million, net of debt discount; their stated principal totaled $2.5 million. The six-month period included $385,800 of net financing cash, including $430,000 from common-stock sales and $220,000 of convertible-note proceeds, offset in part by $240,000 of distributions to a non-controlling interest.

Material changes versus the prior comparable period

Revenue rose 57.2% for the quarter and 53.6% for the six months, reflecting new hospital contracts, growth and expanded services with existing clients, and the 2012 acquisition of Verdugo Medical Management. Cost of services grew faster than revenue, and gross margin fell to 8.7% from 26.9% in the quarter and to 16.1% from 22.8% for the six months. Management attributed pressure in part to physician costs and higher stock-based compensation.

General and administrative expense rose to $1.581 million for the quarter and $2.872 million for the six months, with management citing higher stock-based compensation, growth-related staffing and professional costs, and spending on the ACO and Maverick Medical Group (MMG) initiatives. Operating losses consequently widened. Net losses were lower than in 2012, primarily because the prior-year periods included large non-cash losses on changes in fair value of derivative liabilities; the company reported no such loss in 2013.

Outlook, risks and unusual items

• Going concern: Management said planned operating losses could continue through fiscal 2014 and that liquidity might be insufficient for the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern. It warned that failure to raise substantial additional capital in time could force it to cease operations; its financing plans carried no assurance of success.
• Growth initiatives: MMG and ApolloMed Care Clinic (ACC) were newly formed and had no revenue as of the reporting period; the ACO, MMG and ACC required working capital. The company entered management agreements with MMG in February and ACC in July, each with a 20-year initial term.
• Subsequent event: On September 1, 2013, the company acquired Los Angeles-area clinic assets for $250,000: $100,000 at closing and the remainder in monthly installments under a non-interest-bearing note.
• Controls: Management concluded disclosure controls and internal controls over financial reporting were ineffective, identifying material weaknesses involving absent written control documentation, insufficient segregation of duties, and inadequate review and supervision. Remediation was underway.
• Other risks: The filing cites medical-malpractice claims, uncertainty over insurance availability and adequacy, and regulatory compliance risks for Medicare and Medicaid. It reports no off-balance-sheet arrangements and no defaults upon senior securities.

Important facts for investors to verify

• Confirm the issuer and period: this document identifies Apollo Medical Holdings, Inc. and a July 31, 2013 reporting date, notwithstanding the request metadata naming Astrana Health.
• Assess the company’s funding runway, near-term debt maturities, and ability to raise additional capital in light of the explicit going-concern warning.
• Track whether revenue growth translates into improved gross margins and lower operating losses, particularly as new initiatives require working capital.
• Review dilution exposure from convertible notes, warrants, options and equity offerings; the filing reported 35.9 million common shares outstanding and substantial reserved shares.
• Monitor remediation of the disclosed material weaknesses and review customer concentration. The filing’s revenue-concentration wording is unclear, though two customers represented 16.9% and 9.5% of receivables at July 31, 2013.